These findings can provide novel insights into the gene-based therapy for NSCLC treatment that miR-520a may serve as a potential tool while RRM2 may serve as a potential therapeutic target in the clinical practice. The gene discussed is RRM2; the disease is non-small cell lung carcinoma.